To evaluate the neurological safety and clinical efficacy of darifenacin and mirabegron in patients with a history of cerebrovascular accident (CVA) who had overactive bladder (OAB) symptoms.

This prospective randomized study, approved by the institute’s ethics committee, was carried out at a tertiary care center from December 2018 to June 2020.